New drug targets hard-to-treat cancer mutation in early trial
NCT ID NCT07456046
First seen Mar 18, 2026
Summary
This early-stage study tests a new drug, D3S-003, in people with advanced solid tumors that have a specific genetic change called KRAS p.G12D. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 42 participants whose cancer has not responded to standard treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12D are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
D3 Bio Investigative Site 1103
RECRUITINGRandwick, New South Wales, 2031, Australia
-
D3 Bio Investigative Site 1201
RECRUITINGSeoul, 03080, South Korea
-
D3 Bio Investigative Site 1202
RECRUITINGSeoul, 06591, South Korea
-
D3 Bio Investigative Site 1203
RECRUITINGSeoul, 03722, South Korea
-
D3 Bio Investigative Site 1402
RECRUITINGSan Antonio, Texas, 78229, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.